Cancer Immunotherapy via Disruption of Integrin αvβ3 and CD47 Costabilization on Cancer Cell Surface

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• CD47/SIRPα signaling allows cancer cells to evade macrophage phagocytosis, presenting a therapeutic target.
• Current CD47-based therapies face safety concerns, notably anemia, limiting their clinical application.

Purpose of the Study:

• To investigate a CD47-SIRPα immune checkpoint treatment that mitigates anemic side effects.
• To selectively target the CD47 and integrin αvβ3 costabilization on cancer cells, sparing erythrocytes.

Main Methods:

• Multiplexed immunofluorescence analysis of 119 clinical breast cancer tissues.
• Development and application of the engineered peptide PSFL-NK13 to disrupt CD47-integrin αvβ3 interaction.

Main Results:

• Identified costabilization of CD47 and integrin αvβ3 on cancer cell surfaces, absent in erythrocytes.
• PSFL-NK13 peptide effectively disrupted this interaction, enhancing macrophage phagocytosis.
• Demonstrated delayed tumor growth without inducing anemia or promoting angiogenesis.

Conclusions:

• A novel therapeutic strategy targeting the CD47-integrin αvβ3 interaction offers a safer approach for cancer immunotherapy.
• This method overcomes anemia side effects associated with traditional CD47 blockade therapies.
• The findings suggest broader applicability for this strategy across various tumor types.